MedTrace Logo

CIS001 Extension Study of Cyclosporine Inhalation Solution

NCT00938236 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-09-17

No results posted yet for this study

Summary

This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.

Conditions

  • Lung Transplant

Interventions

DRUG

Cyclosporine Inhalation Solution (CIS)

Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration

Sponsors & Collaborators

  • APT Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Bruce A Johnson, MD · University of Pittsburgh

  • Jeffrey Golden, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00938236 on ClinicalTrials.gov